Cargando…
Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project
INTRODUCTION: Amidst growing consensus that stakeholder decision-making during drug development should be informed by an understanding of patient preferences, the Innovative Medicines Initiative project ‘Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle’ (PREFER) is developi...
Autores principales: | Falahee, Marie, Simons, Gwenda, DiSantostefano, Rachael L, Valor Méndez, Larissa, Radawski, Christine, Englbrecht, Matthias, Schölin Bywall, Karin, Tcherny-Lessenot, Stephanie, Kihlbom, Ulrik, Hauber, Brett, Veldwijk, Jorien, Raza, Karim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039213/ https://www.ncbi.nlm.nih.gov/pubmed/36916312 http://dx.doi.org/10.1136/bmjopen-2020-045851 |
Ejemplares similares
-
Preferences for preventive treatments for rheumatoid arthritis: discrete choice survey in the UK, Germany and Romania
por: Simons, Gwenda, et al.
Publicado: (2022) -
Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations
por: Simons, Gwenda, et al.
Publicado: (2022) -
Maximum Acceptable Risk Estimation Based on a Discrete Choice Experiment and a Probabilistic Threshold Technique
por: Veldwijk, Jorien, et al.
Publicado: (2023) -
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance
por: Simons, Gwenda, et al.
Publicado: (2022) -
Patient preferences on rheumatoid arthritis second-line treatment: a discrete choice experiment of Swedish patients
por: Bywall, Karin Schölin, et al.
Publicado: (2020)